Drug Trial Radar · NCT04166721
WaKING: Wnt and checKpoint INhibition in Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Feb 11, 2020
Primary completion
Mar 30, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Royal Marsden NHS Foundation TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicentre open-label non-randomised, Single Stage Ahern Design (with a 3+3 design for the safety run-in) phase II clinical trial of DKN-01 plus atezolizumab in patients with advanced unresectable or metastatic OGA who have progressed following chemotherapy.
Conditions
- Metastatic Esophageal Cancer
- Metastatic Gastric Cancer
Interventions
AtezolizumabDrug
Immunotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety run-in phase: To recommend a safe and tolerable dose of combination DKN-01 and atezolizumab for use in the main (Phase IIB efficacy) phase of this trial.Time frame: The DLT period is 28 days from the start of the combination of DKN-01 and atezolizumab for any given patient (i.e. from C2 D1)
- Main phase IIB (efficacy) phase: Best objective response rate (ORR) using RECIST 1.1 criteriaTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.